{
  "main_header": {
    "sid": 479596,
    "name": "Brawn Biotech",
    "stock_name": "Brawn Biotech",
    "full_name": "Brawn Biotech Ltd",
    "name_url": "stocks-analysis/brawn-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "19.95",
    "chg": 0.95,
    "chgp": "5.0%",
    "dir": 1,
    "prev_price": "19.00",
    "mcapval": "5.99 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530207,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "India SENSEX",
    "isin": "INE899B01015",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "817 ",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/brawn-biotech-479596-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brawn-biotech-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-weaknesses-3931226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BrawnBiotechLtd_mojoScore_3931226.png",
        "date": "2026-04-03 08:01:41",
        "description": "Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 2 April 2026. This revision reflects a deterioration across multiple key parameters including technical indicators, valuation metrics, financial trends, and overall quality assessment. The downgrade comes amid a sharp decline in share price and persistent operational challenges, signalling heightened risk for investors."
      }
    ],
    "total": 2,
    "sid": "479596",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/brawn-biotech-479596"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "30-May-2026",
      "details": "Newspaper publication of Audited Financial Results for Quarter and Year ended 31.03.2026",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "30-May-2026",
      "details": "BSE Intimation for Non-Applicability of Annual Secretarial Compliance Report under Regulation 24A",
      "source": "BSE"
    },
    {
      "caption": "Intimation Regarding Non-Applicability Of Regulation 23(9)",
      "datetime": "30-May-2026",
      "details": "Intimation regarding non-applicability of Regulation 23(9)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Brawn Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 12 Sep 18",
          "dt": "2018-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Brawn Biotech Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses

2026-04-03 08:01:41

Brawn Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 2 April 2026. This revision reflects a deterioration across multiple key parameters including technical indicators, valuation metrics, financial trends, and overall quality assessment. The downgrade comes amid a sharp decline in share price and persistent operational challenges, signalling heightened risk for investors.

Read More

View All News